Pathos Ai announced it raised $283 Million in an initial filing from an offering of $400 Million

Company

Location

About

Pathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies. Pathos has raised over $100 million to accelerate the development of precision medicines and to expand its platform, combining computational approaches across multimodal real-world data and patient-derived biological models.